Numerous clinical trials have assessed ATR and CHK1 inhibitors in NSCLC, revealing encouraging therapeutic results (NCT02589522, NCT02873975, and NCT01115790) [103]. The gene discussed is CHEK1; the disease is non-small cell lung carcinoma.